Past, present and future of Estetrol (E4); a natural fetal estrogen for human use
Estetrol (E4) is a natural estrogen produced by the fetal liver with a distinctive pharmacologic profile separating it from other natural and synthetic estrogens. Encompassing 25 years of research and development, this review summarizes the history, biochemistry, pharmacology, clinical development, and potential future applications of E4. Essential features of E4 are (1) its high oral bioavailability, long half-life and minimal binding to sex hormone-binding globulin (SHBG), enabling once-daily oral use, and (2) the limited effects on liver function, especially on hemostatic factors, resulting in a lower risk of venous thromboembolism compared to other natural and synthetic estrogens. Estetrol is further characterized as a natural estrogen with selective tissue activity, with a limited impact on breast tissue and cardiovascular and metabolic parameters, while preserving efficacy including bone mass protection. Estetrol therefore has the potential for a markedly improved safety profile. Clinically, the E4/drospirenone (DRSP) combined oral contraceptive (COC) is available worldwide since 2022 and provides effective contraception, a predictable bleeding profile, and a favorable tolerability profile. In phase 2 and 3 studies in postmenopausal women, oral E4 improves vasomotor symptoms, vaginal and urogenital complaints, and quality of life and wellbeing. Ongoing research is exploring wider uses, including combination with the oral GnRH antagonist relugolix for a COC with a focus on the perimenopausal transition and possible applications of E4 in gynecology, endocrinology, obstetrics, neurology and oncology, especially the treatment of advanced breast and prostate cancer.
Authors
- Kristina Gemzell‐Danielsson (ORCID: https://orcid.org/0000-0001-6516-1444)
- Herjan J.T. Coelingh Bennink (ORCID: https://orcid.org/0000-0003-1550-9400)
- Frank Z. Stanczyk (ORCID: https://orcid.org/0000-0002-3607-121X)
- Karolina Afors (ORCID: https://orcid.org/0000-0002-5663-7612)
- Carolyn L. Westhoff (ORCID: https://orcid.org/0000-0002-3622-8846)
- Alessandra Graziottin (ORCID: https://orcid.org/0000-0001-7973-424X)
- Giuseppe Benagiano (ORCID: https://orcid.org/0000-0002-3168-4594)
- Jonathan Douxfils (ORCID: https://orcid.org/0000-0002-7644-5298)
Institutions
- University of Southern California (US)
- University of Verona (IT)
- University College Hospital (GB)
- Karolinska University Hospital (SE)
- University of Namur (BE)
- Columbia University Irving Medical Center (US)
- Karolinska Institutet (SE)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Endocrine Reviews
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1210/endrev/bnag045
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00